Literature DB >> 10926623

Effects of short-term oral salbutamol administration on exercise endurance and metabolism.

K Collomp1, R Candau, F Lasne, Z Labsy, C Préfaut, J De Ceaurriz.   

Abstract

The present study examined whether oral short-term administration of salbutamol (Sal) modifies performance and selected hormonal and metabolic variables during submaximal exercise. Eight recreational male athletes completed two cycling trials at 80-85% peak O(2) consumption until exhaustion after either gelatin placebo (Pla) or oral Sal (12 mg/day for 3 wk) treatment, according to a double-blind and randomized protocol. Blood samples were collected at rest, after 5, 10, and 15 min, and at exhaustion to determine growth hormone (GH), cortisol, testosterone, triiodothyronine (T(3)), C peptide, free fatty acid (FFA), blood glucose, lactate, and blood urea values. Time of cycling was significantly increased after chronic Sal intake (Sal: 30.5 +/- 3.1 vs. Pla: 23.7 +/- 1.6 min, P < 0.05). No change in any variable was found before cycling except a decrease in blood urea concentration and an increase in T(3) after Sal that remained significant throughout the exercise test (P < 0.05). Compared with rest, exercise resulted in a significant increase in GH, cortisol, testosterone, T(3), FFAs, and lactate and a decrease in C peptide after both treatments with higher exercise FFA levels and exhaustion GH concentrations after Sal (P < 0.05). Sal but not Pla significantly decreased exercise blood glucose levels. From these data, short-term Sal intake did appear to improve performance during intense submaximal exercise with concomitant increase in substrate availability and utilization, but the exact mechanisms involved need further investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10926623     DOI: 10.1152/jappl.2000.89.2.430

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  12 in total

1.  Acute supra-therapeutic oral terbutaline administration has no ergogenic effect in non-asthmatic athletes.

Authors:  Anthony M J Sanchez; Fabio Borrani; Marie Amélie Le Fur; Anais Le Mieux; Virgile Lecoultre; Guillaume Py; Christophe Gernigon; Katia Collomp; Robin Candau
Journal:  Eur J Appl Physiol       Date:  2012-07-06       Impact factor: 3.078

Review 2.  β₂-Agonists and physical performance: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Babette M Pluim; Olivier de Hon; J Bart Staal; Jacqueline Limpens; Harm Kuipers; Shelley E Overbeek; Aeilko H Zwinderman; Rob J P M Scholten
Journal:  Sports Med       Date:  2011-01-01       Impact factor: 11.136

Review 3.  Inhaled beta2 agonists and performance in competitive athletes.

Authors:  W Kindermann; T Meyer
Journal:  Br J Sports Med       Date:  2006-07       Impact factor: 13.800

Review 4.  Do inhaled beta(2)-agonists have an ergogenic potential in non-asthmatic competitive athletes?

Authors:  Wilfried Kindermann
Journal:  Sports Med       Date:  2007       Impact factor: 11.136

Review 5.  Use of prescription drugs in athletes.

Authors:  Antti Alaranta; Hannu Alaranta; Ilkka Helenius
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

6.  Acute impact of inhaled short acting b2-agonists on 5 km running performance.

Authors:  John Dickinson; Jiu Hu; Neil Chester; Mike Loosemore; Greg Whyte
Journal:  J Sports Sci Med       Date:  2014-05-01       Impact factor: 2.988

7.  Effects of β2-adrenergic stimulation on exercise capacity in normal subjects.

Authors:  S P Beloka; C Janssen; E Woff; E Brassine; G Deboeck; J Randria; V Philippart de Foy; P van de Borne; R Naeije
Journal:  Eur J Appl Physiol       Date:  2011-02-16       Impact factor: 3.078

Review 8.  beta2-Agonists at the Olympic Games.

Authors:  Kenneth D Fitch
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

9.  Salbutamol intake and substrate oxidation during submaximal exercise.

Authors:  A Arlettaz; B Le Panse; H Portier; A-M Lecoq; R Thomasson; J De Ceaurriz; K Collomp
Journal:  Eur J Appl Physiol       Date:  2008-10-17       Impact factor: 3.078

10.  In vitro effects of Beta-2 agonists on skeletal muscle differentiation, hypertrophy, and atrophy.

Authors:  Francesca Wannenes; Loretta Magni; Matteo Bonini; Ivan Dimauro; Daniela Caporossi; Costanzo Moretti; Sergio Bonini
Journal:  World Allergy Organ J       Date:  2012-06       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.